Related Experiment Video

Updated: May 7, 2026

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice

Thomas Helleday1

  • 1Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.

Current Opinion in Oncology
|October 8, 2013
PubMed
Abstract

Insights

Poly (ADP-ribose) polymerase (PARP) inhibitors and other DNA repair inhibitors show promise for cancer treatment. Well-designed clinical trials are crucial for optimizing their use and minimizing toxicity in patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • DNA repair inhibitors, including poly (ADP-ribose) polymerase (PARP) inhibitors, are under investigation for cancer therapy.
  • These agents offer potential for long-term disease control or cures, similar to chemotherapy.
  • Clinical trial design for DNA repair inhibitors is complex due to potential normal tissue toxicity and variable efficacy.

Purpose of the Study:

  • To review recent findings on the mechanism of action of PARP inhibitors and other DNA repair inhibitors.
  • To explore how genetic background and DNA repair pathway interactions influence treatment strategies.
  • To discuss the role of these inhibitors in monotherapy and combination treatments for various cancers.

Main Methods:

  • Review of recent scientific literature and clinical trial data.
  • Analysis of the interplay between different DNA repair pathways.
  • Examination of genetic factors influencing response to DNA repair inhibitors.

Main Results:

  • Recent findings elucidate the mechanisms of PARP inhibitors and other DNA repair inhibitors.
  • The genetic background of tumors and the interaction of DNA repair pathways are critical for selecting appropriate cancer types and combination strategies.
  • Poly (ADP-ribose) polymerase inhibitors in BRCA-mutated cancers exemplify successful application of synthetic lethality in personalized cancer therapy.

Conclusions:

  • There is substantial evidence supporting DNA repair inhibitors as a viable anticancer strategy.
  • Well-designed clinical trials are essential to harness the full potential of these agents.
  • Individualized therapy, guided by genetic profiling, is key to maximizing the benefits of DNA repair inhibitors.

More Related Videos

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

Characterizing DNA Repair Processes at Transient and Long-lasting Double-strand DNA Breaks by Immunofluorescence Microscopy08:31

Characterizing DNA Repair Processes at Transient and Long-lasting Double-strand DNA Breaks by Immunofluorescence Microscopy

Published on: June 8, 2018

Related Concept Videos

Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart, a...
Translesion DNA Polymerases02:10

Translesion DNA Polymerases

Translesion (TLS) polymerases rescue stalled DNA polymerases at sites of damaged bases by replacing the replicative polymerase and installing a nucleotide across the damaged site. Doing so, TLS allows additional time for the cell to repair the damage before resuming regular DNA replication.
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...